Zenas BioPharma (ZBIO) Return on Capital Employed (2024 - 2026)

Zenas BioPharma's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 83.86% for Q1 2026.

• In Q1 2026, Return on Capital Employed fell 2650.0% year-over-year to 83.86%; the TTM figure through Mar 2026 stood at 83.86% (down 2650.0% YoY), while the FY2025 annual figure was 121.93%, down 2063.0% from the prior year.
• Return on Capital Employed was 83.86% for Q1 2026 at Zenas BioPharma, up from 132.01% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 49.75% in Q4 2024 to a low of 132.01% in Q4 2025.
• Historically, Return on Capital Employed has averaged 79.05% across 3 years, with a median of 75.67% in 2025.
• The sharpest annual moves came in 2025 and 2026: Return on Capital Employed sank 8225 bps in 2025, then plunged 2650 bps in 2026.
• A 3-year view of Return on Capital Employed shows it stood at 49.75% in 2024, then slumped by 165 bps to 132.01% in 2025, then jumped by 36 bps to 83.86% in 2026.
• The last three Return on Capital Employed figures came in at 83.86% (Q1 2026), 132.01% (Q4 2025), and 78.66% (Q3 2025), per Business Quant data.